A broad collaboration is underway between the World Health Organization (including TDR) and external partners to assess the consequences to mothers and their newly born children of drug exposure during pregnancy.
The World Health Organization Central registry for epidemiological surveillance of drug safety in pregnancy is a collaborative initiative to generate reliable evidence on the safety of drugs during pregnancy. This work is developed by the Special Programme for Research and Training in tropical diseases (TDR) in collaboration with other WHO departments, in particular the HIV department, which recommends toxicity surveillance during pregnancy in the context of antiretroviral use.
Our purpose is to facilitate pooling of safety data issued from local or national pregnancy exposure registries or collected in birth outcome surveillance programmes to support early detection of any potential signal of teratogenicity and provide evidence to inform treatment guidelines for pregnant patients.
The pooled data will only be accessible to WHO, and the WHO will undertake periodic analysis of the data collected within the framework of signal detection.
Countries, surveillance projects and researchers are invited to contribute data.
This free app contains images of major externally visible birth defects, with definitions and ICD codes, as well as video material on the newborn examination, information on Congenital Zika Syndrome and limited other syndromes.
For more information, contact Dr Corinne Merle at TDR
